Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is widely used for CLL therapy, both as first-line regimen and for relapsed/refractory (R/R) cases [77,78]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.